Key result
Thrombus aspiration during primary PCI was not significantly associated with reduced one-year mortality compared to no aspiration in STEMI patients (adjusted HR 0.75; 95% CI 0.47-1.20; p=0.23).
Why the study?
Does thrombus aspiration during primary percutaneous coronary intervention reduce mortality in real-world STEMI patients?
Cohort (n=2,552)
Does thrombus aspiration during primary percutaneous coronary intervention reduce mortality in real-world STEMI patients?
In a real-world cohort of STEMI patients, the use of thrombus aspiration during primary PCI did not significantly improve in-hospital or one-year mortality compared to PCI alone.
No mortality benefit seen with thrombus aspiration in this STEMI cohort; leaves open need for randomized confirmation in selected patients.
It was the purpose of this study to assess the effect of thrombus aspiration (TA) during primary percutaneous coronary intervention (PPCI) on reperfusion and clinical outcome in a real-world STEMI population. The decision to use TA (Export catheter, Medtronic) was at the discretion of the treating cardiologist. The primary endpoint was mortality at short (in-hospital) and long term (one year) follow-up. Secondary end points were post-PCI TIMI flow, residual ST deviation and enzymatic infarct size. Cox proportional hazard models (propensity-weighted) and logistic regression analysis were used to adjust for known covariates, associated with mortality. We performed a retrospective analysis of prospectively collected data on 2,552 consecutive PPCI-treated STEMI patients between 2007 and 2010. Use of TA increased from 6.9% in 2007 to 62.2% in 2010 (p<0.001). TA was performed in 899 patients (35.2%). In-hospital and one-year mortality rates were 3.0% and 6.0%, respectively, in the TA group and 3.5% and 7.6% in the no-TA group. After multivariate analysis, TA was not significantly associated with in-hospital mortality (adjusted odds ratio [OR]: 0.70; 95% confidence interval [CI]: 0.33-1.49, p=0.36) nor one year mortality (adjusted hazard ratio [HR]: 0.75, 95%CI: 0.47-1.20, p=0.23) or cardiac mortality (HR: 0.81; 95%CI: 0.45-1.46, p=0.49). After matching on the propensity score, the HR in the TA group for one year mortality was 0.70 (95%CI: 0.41-1.20, p=0.19) and for one-year cardiac mortality 0.70 (95%CI: 0.36-1.34, p=0.28). In conclusion, no significant relationship of TA with one of the secondary end points was found. The use of TA increased over the last years but clinical outcome was similar in both groups (TA vs no-TA) in this large cohort of real-world, unselected STEMI patients.
No takes yet. Share an insight, caveat, or question.
Kılıç et al. (2013) conducted a cohort in STEMI (n=2,552). Thrombus aspiration vs. No thrombus aspiration was evaluated on Mortality at short (in-hospital) and long term (one year) follow-up (HR 0.75, 95% CI 0.47-1.20, p=0.23). Thrombus aspiration during primary PCI was not significantly associated with reduced one-year mortality compared to no aspiration in STEMI patients (adjusted HR 0.75; 95% CI 0.47-1.20; p=0.23).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: